Current evidence supports that inflammation is a major driving force in patients with CAD, underlying the initiation of coronary plaques, their unstable progression, and eventual disruption; numerous studies in this field had been performed and revealed that several potential inflammatory biomarkers including high sensitive C-reactive protein (hs-CRP), interleukin (IL)-6, IL-8 and IL-1β are potent inflammatory mediators in progression of CAD and even they can be used as predictive markers in diagnosis of the severity of disease [8]. Here, IL1B is linked to coronary artery disorder.